In a report released yesterday, Chris Shibutani from Cowen & Co. maintained a Buy rating on Mirati Therapeutics (MRTX). The company’s shares closed yesterday at $104.07, close to its 52-week high of $109.64.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 8.5% and a 45.5% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.
Currently, the analyst consensus on Mirati Therapeutics is a Moderate Buy with an average price target of $113.90.
See today’s analyst top recommended stocks >>
The company has a one-year high of $109.64 and a one-year low of $28.50. Currently, Mirati Therapeutics has an average volume of 762.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat.